[Combination of interferon alpha-1b, interleukin-2 and thalidomide as maintenance therapy on acute myeloid leukemia patients with negative minimal residual disease]

Zhonghua Xue Ye Xue Za Zhi. 2020 Sep 14;41(9):766-769. doi: 10.3760/cma.j.issn.0253-2727.2020.09.011.
[Article in Chinese]
No abstract available

MeSH terms

  • Antineoplastic Agents / therapeutic use
  • Humans
  • Interferon-alpha / therapeutic use
  • Interleukin-2* / therapeutic use
  • Leukemia, Myeloid, Acute* / drug therapy
  • Maintenance
  • Neoplasm, Residual
  • Thalidomide* / therapeutic use

Substances

  • Antineoplastic Agents
  • Interferon-alpha
  • Interleukin-2
  • Thalidomide

Grants and funding

基金项目：河南省医学科技攻关计划省部共建项目（201701027）；河南省医学科技攻关计划项目（省部共建）（201701028）；河南省自然科学基金（22180003）